Anti-aging biopharma company raises $40 million to begin human tests
“As people live longer, improving quality of life is paramount,” said Alex Morgan, a partner at Khosla Ventures, who chipped in to fund Rubedo’s first round of venture capital financing. “Rubedo is targeting senescent, or aging, cells that drive age-re… Continue reading Anti-aging biopharma company raises $40 million to begin human tests